Freestone Capital Holdings’s CRISPR Therapeutics CRSP Stock Holding History

Freestone Capital Holdings’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-3,449	Closed	-$224K	–	567
2025 Q3	$224K	Buy	+3,449	New	+$198K	0.01%	486
2024 Q2	–	Sell	-3,628	Closed	-$247K	–	468
2024 Q1	$247K	Hold	3,628	–	–	0.01%	399
2023 Q4	$227K	Buy	+3,628	New	+$201K	0.01%	363
2023 Q3	–	Sell	-3,628	Closed	-$204K	–	389
2023 Q2	$204K	Buy	+3,628	New	+$206K	0.01%	357
2022 Q1	–	Sell	-2,972	Closed	-$225K	–	589
2021 Q4	$225K	Buy	2,972 +164	+6%	+$14.3K	0.01%	453
2021 Q3	$314K	Sell	2,808 -46	-2%	-$5.78K	0.02%	341
2021 Q2	$462K	Buy	+2,854	New	+$347K	0.02%	281
2021 Q1	–	Sell	-439	Closed	-$67.2K	–	537
2020 Q4	$67.2K	Buy	439 +330	+303%	+$39K	﹤0.01%	507
2020 Q3	$9.12K	Buy	+109	New	+$9.67K	﹤0.01%	762

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

GSK plc London $599M AUM

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Freestone Capital Holdings's CRSP Position: Q4 2025 in Review

Freestone Capital Holdings sold out of CRISPR Therapeutics (CRSP) in Q4 2025, closing a stake of 3,449 shares — an estimated $224K sold.

Freestone Capital Holdings first reported a position in CRSP in Q3 2020 and held it in 9 quarters. The position peaked at $462K in Q2 2021. 479 funds tracked by Wall St. Rank hold CRSP as of Q4 2025.

Freestone Capital Holdings reported no remaining CRISPR Therapeutics position as of Q4 2025 after selling out during the quarter.
Freestone Capital Holdings sold 3,449 CRISPR Therapeutics shares in Q4 2025, an estimated $224K.
Freestone Capital Holdings first reported a position in CRISPR Therapeutics in Q3 2020 and held it in 9 quarters.
Freestone Capital Holdings's CRISPR Therapeutics position peaked at $462K in Q2 2021.
479 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2025.

Based on Freestone Capital Holdings's 13F filing for Q4 2025, filed 23 Jan 2026.